AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32348688
Drug: Strength training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength training (ST) with vitamin C (500 mg/day) and E (180 mg/day) supplementation
Trial: 33677172
Drug: Acupuncture with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture with low-level laser therapy (ALLLT)
Trial: 32765053
Drug: Inhaled methoxyflurane
RxNorm normalized name: methoxyflurane Nasal Inhalant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methoxyflurane (3 mL)
Trial: 36043569
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - no treatment
Trial: 36055770
Drug: Moderate Spice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate Spice Diet (MSD) at 3.3 g.d-1.2100 kcal-1
Trial: 36055770
Drug: High Spice
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Spice Diet (HSD) at 6.6 g.d-1.2100 kcal-1
Trial: 36055770
Drug: Low Spice
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Spice Diet (LSD) at 0.5 g.d-1.2100 kcal-1
Trial: 34872531
Drug: Nurse-led SRIT
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led SRIT treatment
Trial: 34597298
Drug: 2-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose regimen of 5-μg NVX-CoV2373
Trial: 34597298
Drug: 2-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-dose regimen of 25-μg NVX-CoV2373
Trial: 39744861
Drug: Best medical
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best medical treatment
Trial: 32643454
Drug: Intradermal minoxidil
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal minoxidil 5% injections
Trial: 32475067
Drug: Everolimus 2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 2.25 mg
Trial: 32900662
Drug: Single 20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 20-mg dexamethasone tablet (fasting)
Trial: 32900662
Drug: Single 20-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 20-mg dexamethasone tablet (fed)
Trial: 33944971
Drug: Euglycaemia (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Euglycaemia (5 mmol/l) with 20 mU [m2 BSA]‐1 min‐1 insulin (Eu20)
Trial: 38749033
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus placebo
Trial: 36332136
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement (1 capsule/day for 8 weeks)
Trial: 36653035
Drug: Probiotic supplement
RxNorm normalized name: Align Probiotic Supplement Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic supplement
Trial: 36202885
Drug: Placebo tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet consumed every hour for 4 h (PLA)
Trial: 35486478
Drug: Oral hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormonal contraceptive pill (OC) during high estradiol (HE) phase
Trial: 35486478
Drug: Oral hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hormonal contraceptive pill (OC) during low estradiol (LE) phase
Trial: 32931763
Drug: Spinal manipulation
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulation therapy (3 sessions, 1 week apart, using Robert Maigne's technique)
Trial: 37852649
Drug: atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin
Trial: 32441852
Drug: Fast enteral
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast enteral advancement (30 mL/kg/d for 1000-1499 g; 40 mL/kg/d for 1500-1999 g)
Trial: 32441852
Drug: Traditional enteral
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional enteral advancement (20 mL/kg/d)
Trial: 33219727
Drug: Onlay preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onlay preparation with EverX Posterior (OE)
Trial: 33219727
Drug: Onlay preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onlay preparation with G‐aenial Universal Flo (OG)
Trial: 33219727
Drug: MOD inlay
RxNorm normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: MOD inlay preparation with EverX Posterior (IE)
Trial: 33219727
Drug: MOD inlay
RxNorm normalized name: MOD-423 hGH analogue
DrugBank: Somatrogon (DB14960)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: MOD inlay preparation with G‐aenial Universal Flo (IG)
Trial: 33219727
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without access cavity preparation (C)
Trial: 33219727
Drug: Onlays with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onlays with G‐aenial Universal Flo
Trial: 32280282
Drug: EE 20
RxNorm normalized name: AcidFree 200mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EE 20 mcg/DRSP 3 mg in an extended regimen (EE/DRSPes group)
Trial: 33719786
Drug: Topical glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glaucoma medications (one-drug, two-drug, three-drug, four-drug regimens)
Trial: 32232637
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m2, single intravenous infusion)
Trial: 36890688
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment
Trial: 35481707
Drug: TransCon CNP
RxNorm normalized name: TransCon CNP
DrugBank: ACP-015 (DB17824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TransCon CNP (75-150 μg CNP/kg)
Trial: 34293624
Drug: Guo Qing
RxNorm normalized name: Guo
DrugBank: Guanosine (DB02857)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guo Qing Yi Tang (GQYT) combined with Western medicine cluster therapy
Trial: 32118347
Drug: Physician-managed titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician-managed titration of Gla-300
Trial: 36779257
Drug: Lumateperone 42
RxNorm normalized name: lumateperone 42 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumateperone 42 mg
Trial: 36779257
Drug: Lumateperone 28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumateperone 28 mg
Trial: 35551318
Drug: Monthly dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly dual injections
Trial: 35551318
Drug: Monthly vaginal
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly vaginal rings
Trial: 33637926
Drug: Personalised Oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalised Oral Hygiene Advice (OHA)
Trial: 34954864
Drug: Neoadjuvant FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant FOLFOX chemotherapy
Trial: 34843870
Drug: Single oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of 25 μg of d3‐vitamin D3
Trial: 34894316
Drug: Structured Postoperative
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Postoperative Treatment (SPT)
Trial: 36802321
Drug: Evolocumab 140
RxNorm normalized name: evolocumab 140 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evolocumab 140 mg every 2 weeks (Q2W)
Trial: 36608978
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy for Body Dysmorphic Disorder (CT‐BDD)
Trial: 33875484
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin icodec titration A (prebreakfast self-measured blood glucose target 80-130 mg/dL; adjustment ±21 units/week; n = 51)
Trial: 33875484
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin icodec titration B (80-130 mg/dL; ±28 units/week; n = 51)
Trial: 33875484
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin icodec titration C (70-108 mg/dL; ±28 units/week; n = 52)
Trial: 33875484
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 units/mL (IGlar U100) (80-130 mg/dL; ±4 units/day; n = 51)
Trial: 33875484
Drug: Insulin icodec
RxNorm normalized name: insulin icodec
DrugBank: Insulin icodec (DB16693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin icodec titration B vs IGlar U100
Trial: 34081614
Drug: Feminizing hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Feminizing hormonal treatment (GAHT) including natural estrogen (estradiol) and testosterone-blocking treatments such as cyproterone acetate, GnRH agonist, or spironolactone.
Trial: 34081614
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate as anti-androgen treatment.
Trial: 36097258
Drug: Oral ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ivermectin (200 μg/kg body weight) twice, 1 week apart
Trial: 36097258
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of BB plus ivermectin
Trial: 33497715
Drug: JWH-018 (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JWH-018 (75 μg/kg body weight)
Trial: 36079749
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g date fruit daily for 12 weeks
Trial: 36079749
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g raisins daily for 12 weeks
Trial: 34537744
Drug: Intrathyroid steroid
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathyroid steroid injections
Trial: 32718924
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (clinical consultations and routine monthly follow-up)
Trial: 35959574
Drug: General treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General treatment group
Trial: 35475852
Drug: 0.015% ingenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.015% ingenol mebutate gel
Trial: 32796456
Drug: Self-myofascial release
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-myofascial release therapy using the INYBI tool
Trial: 32796456
Drug: Myofascial release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofascial release therapy (MRT) of the suboccipital muscles
Trial: 34954424
Drug: Bethanechol (for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bethanechol (for patients receiving 131I dose > 125mCi)
Trial: 34871488
Drug: Monthly combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly combined injectable contraceptives (CIC)
Trial: 34871488
Drug: Combined oral
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined oral contraceptive pills (COC)
Trial: 32191598
Drug: Testosterone administration
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone administration (10 mg daily for 10 weeks)
Trial: 35606235
Drug: S‐268019‐b recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐268019‐b recombinant protein vaccine (5 μg)
Trial: 34326043
Drug: Co-trimoxazole 18
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole 18 mg/kg two times per day (36 mg/kg/day) for 3 months
Trial: 32616067
Drug: Daily hydroxychloroquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily hydroxychloroquine
Trial: 32425361
Drug: Lianhuaqingwen capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lianhuaqingwen capsules (4 capsules, thrice daily for 14 days)
Trial: 35708181
Drug: LYR‐210 (7500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYR‐210 (7500 µg)
Trial: 35708181
Drug: LYR‐210 (2500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LYR‐210 (2500 µg)
Trial: 35511431
Drug: Tetravalent dengue
RxNorm normalized name: dengue virus live antigen, CYD serotype 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetravalent dengue vaccine (TV005)
Trial: 35511431
Drug: Trivalent admixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent admixture vaccine
Trial: 33138974
Drug: Renal replacement
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal replacement therapy
Trial: 32015556
Drug: bNAb therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bNAb therapy during ART interruption
Trial: 38661512
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy
Trial: 35477817
Drug: G-Premio Bond
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Premio Bond (GP)
Trial: 33831316
Drug: HCV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV treatment prescribed
Trial: 33831316
Drug: HCV treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV treatment initiated
Trial: 35421008
Drug: HBOC‐201 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC‐201 infusion (up to 10 bags, equivalent to 3 units erythrocytes)
Trial: 35421008
Drug: HBOC‐201 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBOC‐201 infusion
Trial: 33308110
Drug: Integrative mind-body-medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative mind-body-medicine group program
Trial: 32801202
Drug: 18 mg
RxNorm normalized name: niacin 18 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 mg ferrous bisglycinate
Trial: 32207836
Drug: Ticagrelor and
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor and morphine without naloxone
Trial: 33051342
Drug: PD-1/PD-L1 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1/PD-L1 inhibitors (monotherapy)
Trial: 32493473
Drug: Plasma‐Lyte 148
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma‐Lyte 148 Solution for Infusion (200mls)
Trial: 35262624
Drug: HIPEC (41.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC (41.5 °C, 75 mg/m2 of cisplatin, 90 minutes)
Trial: 35262624
Drug: HIPEC (Interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIPEC (Interval cytoreductive surgery after neoadjuvant chemotherapy)
Trial: 35262624
Drug: Control (Interval
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Interval cytoreductive surgery after neoadjuvant chemotherapy)
Trial: 38896381
Drug: apremilast 30
RxNorm normalized name: apremilast 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apremilast 30 mg twice daily
Trial: 2010180594
Drug: Methylphenidate (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (15 mg, twice a day for one month)
Trial: 33975009
Drug: SARS-CoV-2 IgG
RxNorm normalized name: SARS-CoV-2 IgG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SARS-CoV-2 IgG antibody levels
Trial: 33479188
Drug: Everolimus (EVL)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (EVL) with low-dose tacrolimus (Tac)
Trial: 36071965
Drug: Probiotic chewable
RxNorm normalized name: Rezyst Probiotic Chewable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic chewable tablet (5 × 10^9 CFU/day, n = 47)
Trial: 36198452
Drug: AVX001 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVX001 gel 1%
Trial: 36198452
Drug: AVX001 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AVX001 gel 3%
Trial: 39630680
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle gel
Trial: 36364734
Drug: Oat product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat product providing 3 g of β‐Glucan
Trial: 37697491
Drug: Self-administered questionnaire
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered questionnaire
Trial: 32442355
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual in the community
Trial: 34967166
Drug: Tamsulosin monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin monotherapy
Trial: 34844563
Drug: Nomogram model
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram model for predicting prognosis of patients with CC
Trial: 34996784
Drug: Anticoagulant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulant treatment
Trial: 34326035
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to First Systemic Treatment (TTFST)
Trial: 33743237
Drug: Second intravenous
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second intravenous immunoglobulin dose (SID) 2 g/kg over 5 days
Trial: 32871021
Drug: Electromagnetic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electromagnetic therapy
Trial: 34991704
Drug: Azithromycin mass
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin mass drug administration (MDA)
Trial: 33881530
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate (250 to 1500 mg/d)
Trial: 34050261
Drug: Ionising radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ionising radiation exposure (mean ABM dose 0.14 Gy)
Trial: 32307658
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia (CBT-I) including sleep hygiene information, stimulus control, sleep restriction, and bedtime imagery audio recording.
Trial: 32091032
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (control group).
Trial: 36245835
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium sustained-release tablet (100 mg) once a day for 8 courses (7 days each course)
Trial: 34462343
Drug: CC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC alone
Trial: 34462343
Drug: CC with
RxNorm normalized name: BD Syringe 5cc with Needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC with telemedicine
Trial: 34419082
Drug: MitoQ (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MitoQ (20 mg·day−1)
Trial: 39107737
Drug: Titanium implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium implants
Trial: 32357900
Drug: Oxymetazoline nasal
RxNorm normalized name: oxymetazoline nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline nasal spray
Trial: 35305347
Drug: Intramuscular 10
RxNorm normalized name: Zyprexa IntraMuscular 10mg Powder for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular 10 units (IM group)
Trial: 35305347
Drug: Intravenous 10
RxNorm normalized name: fat emulsion, intravenous 10% intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous 10 units in 100 ml 0.9% NaCl solution over 10-15 min (IV group)
Trial: 33982512
Drug: Classic TCM
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classic TCM prescriptions
Trial: 33223020
Drug: Boost SRS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boost SRS after fractionated radiation therapy
Trial: 34374114
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (MB02, US-bevacizumab, EU-bevacizumab)
Trial: 32782254
Drug: Queens choosing
RxNorm normalized name: queen palm pollen extract
DrugBank: Syagrus romanzoffiana pollen (DB10482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Queens choosing between two empty nesting chambers; no specific dosage or duration mentioned.
Trial: 33506447
Drug: Immunosuppressive agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive agents